Perspectives
perspectives
July 1st, 2025
Why Real-Time Data Access Matters (and How to Make the Most of It)
perspectives
June 24th, 2025
Why Now Is the Time for Specialized, Data-Focused CRO Partners
perspectives
June 17th, 2025
Solving Data Complexity with Real-Time Insights, Predictive AI, and Smarter Decision-Making with Datacise
perspectives
June 10th, 2025
Applying Artificial Intelligence (AI) and Real-World Evidence to Boost Efficiency in Patient Safety Narratives
perspectives
June 3rd, 2025
Choosing the Right Strategy: Parallel, Sequential, and Staggered Regulatory Submissions
perspectives
May 28th, 2025
A Season of Change: Why the REMS Industry Consortium Matters More Than Ever
perspectives
May 20th, 2025
Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors
perspectives
May 6th, 2025
Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn
perspectives
April 24th, 2025
How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy
perspectives
April 8th, 2025
Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements
perspectives
March 27th, 2025
Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs
perspectives
March 6th, 2025
Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products